Efficacy and Safety of Probiotics in the Treatment of Irritable Bowel Syndrome
Weeks of IBS Symptoms in Non-Constipated Irritable Bowel Syndrome: Results From 2 North American Phase 3 Trials (Target 1 and Target 2), Gastroenterology, 2010;138:S64–S5.
34. Posserud I, Stotzer PO, Bjornsson ES, et al., Small intestinal bacterial overgrowth in patients with irritable bowel syndrome, Gut, 2007;56:802–8.
35. Pimentel M, Park S, Mirocha J, et al., The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial, Ann Intern Med, 2006;145:557–63.
36. Boudeau J, Glasser AL, Julien S, et al., Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent- invasive E. coli strains isolated from patients with Crohn's disease, Aliment Pharmacol Ther, 2003;18:45–56.
37. Gopal PK, Prasad J, Smart J, et al., In vitro adherence properties of Lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli, Int J Food Microbiol, 2001;67: 207–16.
38. Cotter PD, Hill C, Ross RP, Bacteriocins: developing innate immunity for food, Nat Rev Microbiol, 2005;3:777–88.
39. Resta-Lenert S, Barrett KE, Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC), Gut, 2003;52:988–97.
40. Gwee KA, Collins SM, Read NW, et al., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 2003;52:523–6.
41. Spiller RC, Jenkins D, Thornley JP, et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 2000;47:804–11.
42. Barbara G, Stanghellini V, De Giorgio R, et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 2004;126:693–702.
43. O'Mahony L, McCarthy J, Kelly P, et al., Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles, Gastroenterology, 2005;128:541–51.
44. Collins SM, Dysregulation of peripheral cytokine production in irritable bowel syndrome, Am J Gastroenterol, 2005;100:2517–8.
45. Dinan TG, Quigley EM, Ahmed SM, et al., Hypothalamic- pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?, Gastroenterology, 2006;130:304–11.
46. Dunlop SP, Hebden J, Campbell E, et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 2006;101:1288–94.
47. Di Giacinto C, Marinaro M, Sanchez M, et al., Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells, J Immunol, 2005;174:3237–46.
48. Hart AL, Lammers K, Brigidi P, et al., Modulation of human dendritic cell phenotype and function by probiotic bacteria, Gut, 2004;53:1602–9.
49. Lee HS, Han SY, Bae EA, et al., Lactic acid bacteria inhibit proinflammatory cytokine expression and bacterial glycosaminoglycan degradation activity in dextran sulfate sodium-induced colitic mice, Int Immunopharmacol, 2008;8:574–80.
50. McCarthy J, O'Mahony L, O'Callaghan L, et al., Double blind, placebo controlled trial of two probiotic strains in interleukin
10 knockout mice and mechanistic link with cytokine balance, Gut, 2003;52:975–80.
51. Rachmilewitz D, Katakura K, Karmeli F, et al., Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis, Gastroenterology, 2004;126:520–8.
52. Madsen K, Cornish A, Soper P, et al., Probiotic bacteria enhance murine and human intestinal epithelial barrier function, Gastroenterology, 2001;121:580–91.
53. Mangell P, Nejdfors P, Wang M, et al., Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability, Dig Dis Sci, 2002;47:511–6.
54. Sheil B, MacSharry J, O'Callaghan L, et al., Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice, Clin Exp Immunol, 2006;144:273–80.
55. O'Hara AM, O'Regan P, Fanning A, et al., Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius, Immunology, 2006;118:202–15.
56. Lawal A, Kern M, Sidhu H, et al., Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients, Gastroenterology, 2006;130:26–33.
57. Verdu EF, Bercik P, Verma-Gandhu M, et al., Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice, Gut, 2006;55:182–90.
58. Ait-Belgnaoui A, Han W, Lamine F, et al., Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction, Gut, 2006;55:1090–4.
59. Liebregts T, Adam B, Bertel A, et al., Effect of E. coli Nissle 1917 on post-inflammatory visceral sensory function in a rat model, Neurogastroenterol Motil, 2005;17:410–4.
60. Rousseaux C, Thuru X, Gelot A, et al., Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors, Nat Med, 2007;13:35–7.
61. McKernan DP, Fitzgerald P, Dinan TG, et al., The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat, Neurogastroenterol Motil, 2010;22(9):1029–35, e268.
62. Mayer EA, Craske M, Naliboff BD, Depression, anxiety, and the gastrointestinal system, J Clin Psychiatry, 2001;62 (Suppl. 8):28–36, discussion 7.
63. Soderholm JD, Perdue MH, Stress and gastrointestinal tract. II. Stress and intestinal barrier function, Am J Physiol Gastrointest Liver Physiol, 2001;280:G7–G13.
64. Soderholm JD, Yang PC, Ceponis P, et al., Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine, Gastroenterology, 2002;123:1099–108.
65. Velin AK, Ericson AC, Braaf Y, et al., Increased antigen and bacterial uptake in follicle associated epithelium induced by chronic psychological stress in rats, Gut, 2004;53:494–500.
66. Eutamene H, Lamine F, Chabo C, et al., Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats, J Nutr, 2007;137:1901–7.
67. Zareie M, Johnson-Henry K, Jury J, et al., Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress, Gut, 2006;55:1553–60.
68. Ait-Belgnaoui A, Eutamene H, Houdeau E, et al., Lactobacillus farciminis treatment attenuates stress-induced
overexpression of Fos protein in spinal and supraspinal sites after colorectal distension in rats, Neurogastroenterol Motil, 2009;21:567-73, e18–9.
69. Kim HJ, Camilleri M, McKinzie S, et al., A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 2003;17:895–904.
70. Kim HJ, Vazquez Roque MI, Camilleri M, et al., A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating, Neurogastroenterol Motil, 2005;17:687–96.
71. Tsuchiya J, Barreto R, Okura R, et al., Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome, Chin J Dig Dis, 2004;5:169–74.
72. Kajander K, Hatakka K, Poussa T, et al., A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention, Aliment Pharmacol Ther, 2005;22:387–94.
73. Kajander K, Myllyluoma E, Rajilic-Stojanovic M, et al., Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota, Aliment Pharmacol Ther, 2008;27:48–57.
74. Halpern GM, Prindiville T, Blankenburg M, et al., Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial, Am J Gastroenterol, 1996;91: 1579–85.
75. O'Sullivan MA, O'Morain CA, Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study, Dig Liver Dis, 2000;32:294–301.
76. Niedzielin K, Kordecki H, Birkenfeld B, A controlled, double- blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome, Eur J Gastroenterol Hepatol, 2001;13:1143–7.
77. Niv E, Naftali T, Hallak R, et al., The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome—a double blind, placebo-controlled, randomized study, Clin Nutr, 2005;24:925–31.
78. Moayyedi P, Ford AC, Talley NJ, et al., The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review, Gut, 59:325–32.
79. Brenner DM, Moeller MJ, Chey WD, et al., The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review, Am J Gastroenterol, 2009;104:1033–49, quiz 50.
80. Whorwell PJ, Altringer L, Morel J, et al., Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, Am J Gastroenterol, 2006;101:1581–90.
81. Guyonnet D, Chassany O, Ducrotte P, et al., Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial, Aliment Pharmacol Ther, 2007;26:475–86.
82. Besselink MG, van Santvoort HC, Buskens E, et al., Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial, Lancet, 2008;371:651–9.
83. Irvine EJ, Whitehead WE, Chey WD, et al., Design of treatment trials for functional gastrointestinal disorders, Gastroenterology, 2006;130:1538–51.
84. Shanahan F, Gut microbes: from bugs to drugs, Am J Gastroenterol, 2010;105:275–9.
US GASTROENTEROLOGY & HEPATOLOGY REVIEW
53
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100